13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
84 檔
16.6%
At the close of Q2 2025, Perceptive Advisors LLC disclosed equity holdings valued at approximately $6.7B, spread across 84 reported holdings.
In Q2 2025, Perceptive Advisors LLC adopted a defensive or profit-taking posture, trimming 33 positions and completely liquidating 23 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, ASND, ACLXGBX) accounted for 16.6% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 19.31% | — | -16.09% | |
| 2 | ASND | Ascendis Pharma A/S | Stock-Other | 6.17% | -6.84% | EXIT | |
| 3 | ACLXGBX | Arcellx Inc | Stock-Other | 6.05% | — | -15.32% | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 5.67% | +0.28% | -5.11% | |
| 5 | NUVL | Nuvalent Inc-a | Stock-Other | 3.89% | -0.23% | -15.84% | |
| 6 | AORT | Artivion Inc | Stock-Other | 3.22% | -0.58% | — | |
| 7 | MGTX | MeiraGTx Holdings plc | Stock-Other | 3.05% | +0.44% | +0.36% | |
| 8 | INSM | Insmed Inc | Stock-Healthcare | 2.43% | — | +27.68% | |
| 9 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.26% | -0.05% | -34.16% | |
| 10 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.20% | -0.73% | -1.54% | |
| 11 | SLDB | Solid Biosciences Inc | Stock-Other | 2.15% | +0.11% | — | |
| 12 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.90% | +0.08% | +5.29% | |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.88% | — | +0.36% | |
| 14 | ✓ | Immatics NV | Stock-Other | 1.87% | -0.42% | — | |
| 15 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.81% | — | +15.50% | |
| 16 | OMDA | Omada Health Inc | Stock-Other | 1.65% | +0.07% | — | |
| 17 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.57% | — | -65.46% | |
| 18 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.39% | -0.18% | — | |
| 19 | ✓ | Merus N V | Stock-Other | 1.38% | — | +2.56% | |
| 20 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.34% | — | -71.43% | |
| 21 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.29% | — | — | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.27% | +0.01% | -24.83% | |
| 23 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.19% | -0.17% | EXIT | |
| 24 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.17% | -2.59% | -23.24% | |
| 25 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.11% | +0.16% | NEW | |
| 26 | CAI | Caris Life Sciences Inc | Stock-Other | 1.09% | — | — | |
| 27 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.92% | +0.71% | NEW | |
| 28 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.91% | -0.46% | +11.08% | |
| 29 | ADMA | Adma Biologics Inc | Stock-Healthcare | 0.88% | -0.07% | -5.08% | |
| 30 | BBNX | Beta Bionics Inc | Stock-Other | 0.86% | +0.04% | — | |
| 31 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.85% | +2.03% | -33.88% | |
| 32 | EOLS | Evolus Inc | Stock-Other | 0.85% | +0.16% | -40.06% | |
| 33 | CELC | Celcuity Inc | Stock-Other | 0.81% | -1.95% | -30.86% | |
| 34 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.79% | -0.75% | -2.85% | |
| 35 | SION | Sionna Therapeutics Inc | Stock-Other | 0.78% | +0.08% | -2.80% | |
| 36 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.77% | -0.06% | -44.09% | |
| 37 | RGEN | Repligen CORP | Stock-Healthcare | 0.77% | -0.14% | +27.89% | |
| 38 | PODD | Insulet CORP | Stock-Healthcare | 0.70% | — | -15.66% | |
| 39 | OM | Outset Medical Inc | Stock-Other | 0.59% | -0.01% | — | |
| 40 | ZYME | Zymeworks Inc | Stock-Other | 0.59% | -0.08% | -31.61% | |
| 41 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.59% | -0.34% | — | |
| 42 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.58% | — | -56.32% | |
| 43 | CRL | Charles River Laboratories | Stock-Healthcare | 0.56% | +0.48% | NEW | |
| 44 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.56% | -4.08% | EXIT | |
| 45 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.52% | -0.05% | -8.10% | |
| 46 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.48% | -0.12% | +0.65% | |
| 47 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.46% | +0.45% | +268.67% | |
| 48 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.46% | +0.80% | — | |
| 49 | OBIO | Orchestra Biomed Holdings In | Stock-Other | 0.46% | -0.09% | — | |
| 50 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.41% | -0.54% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | +6.2% | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | +4.6% | -16.09% | Trim |
| 3 | OMDA | Omada Health Inc | +1.7% | NEW | New buy |
| 4 | ROIV | Roivant Sciences Ltd. | +1.4% | NEW | New buy |
| 5 | CAI | Caris Life Sciences Inc | +1.1% | NEW | New buy |
| 6 | INSM | Insmed Inc | +1.1% | +27.68% | Add |
| 7 | XBI | Ss Spdr S&p Biotech ETF | +0.9% | NEW | New buy |
| 8 | AMLX | Amylyx Pharmaceuticals Inc | +0.9% | +0.36% | Add |
| 9 | RYTM | Rhythm Pharmaceuticals Inc | +0.9% | -5.11% | Trim |
| 10 | NBIX | Neurocrine Biosciences Inc | +0.8% | +154.92% | Add |
| 11 | AORT | Artivion Inc | +0.8% | — | Unchanged |
| 12 | AKRO | Akero Therapeutics Inc | +0.7% | +15.50% | Add |
| 13 | BSX | Boston Scientific CORP | +0.7% | +115.38% | Add |
| 14 | CTMX | Cytomx Therapeutics Inc | +0.6% | NEW | New buy |
| 15 | SLDB | Solid Biosciences Inc | +0.6% | — | Unchanged |
| 16 | CRL | Charles River Laboratories | +0.6% | NEW | New buy |
| 17 | TVTX | Travere Therapeutics Inc | +0.5% | NEW | New buy |
| 18 | APGE | Apogee Therapeutics Inc | +0.4% | +5.29% | Add |
| 19 | ✓ | Immatics NV | +0.4% | — | Unchanged |
| 20 | RARE | Ultragenyx Pharmaceutical In | +0.4% | NEW | New buy |
| 21 | ✓ | Merus N V | +0.4% | +2.56% | Add |
| 22 | KYMR | Kymera Therapeutics Inc | +0.3% | NEW | New buy |
| 23 | NRIX | Nurix Therapeutics Inc | +0.3% | +268.67% | Add |
| 24 | PTGX | Protagonist Therapeutics Inc | +0.3% | -1.54% | Trim |
| 25 | SION | Sionna Therapeutics Inc | +0.3% | -2.80% | Trim |
| 26 | PEN | Penumbra Inc | +0.3% | NEW | New buy |
| 27 | CAPR | Capricor Therapeutics Inc | +0.3% | NEW | New buy |
| 28 | ✓ | Crescent Biopharma Inc. | +0.3% | NEW | New buy |
| 29 | OM | Outset Medical Inc | +0.3% | — | Unchanged |
| 30 | CRVS | Corvus Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 31 | SEPN | Septerna Inc | +0.2% | NEW | New buy |
| 32 | ADGM | Adagio Medical Holdings Inc | +0.2% | +0.65% | Add |
| 33 | ISRG | Intuitive Surgical Inc | +0.2% | +11.08% | Add |
| 34 | GMED | Globus Medical Inc - A | +0.2% | NEW | New buy |
| 35 | ✓ | Envveno Medical CORP | +0.2% | NEW | New buy |
| 36 | RGEN | Repligen CORP | +0.2% | +27.89% | Add |
| 37 | BBNX | Beta Bionics Inc | +0.2% | — | Unchanged |
| 38 | LYRA | Lyra Therapeutics Inc | +0.1% | NEW | New buy |
| 39 | CATBUSD | Astria Therapeutics Inc | +0.1% | — | Unchanged |
| 40 | RAPT | Rapt Therapeutics Inc | +0.1% | NEW | New buy |
| 41 | MGTX | MeiraGTx Holdings plc | 0% | +0.36% | Add |
| 42 | TRIB | Trinity Biotech Plc-spon Adr | 0% | NEW | New buy |
| 43 | PODD | Insulet CORP | 0% | -15.66% | Trim |
| 44 | FBRX | Forte Biosciences Inc | 0% | NEW | New buy |
| 45 | SCPH | Scpharmaceuticals Inc | 0% | — | Unchanged |
| 46 | ✓ | Athira Pharma Inc | 0% | — | Unchanged |
| 47 | ✓ | Helix Acquisition CORP Ii | — | — | Unchanged |
| 48 | IRD | Opus Genetics Inc | — | — | Unchanged |
| 49 | APYX | Apyx Medical CORP | — | — | Unchanged |
| 50 | LXEO | Lexeo Therapeutics Inc | — | — | Unchanged |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 84 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ASND
市值: $166.4M
Top Position Liquidated / Trimmed
ITCIEUR
前期市值: $103.7M
During Q2 2025, Perceptive Advisors LLC's top holdings by market value included VRNA (19.3%)、ASND (6.2%)、ACLXGBX (6.0%). The largest single position, VRNA, represented 19.3% of total portfolio value.
In Q2 2025, Perceptive Advisors LLC made 89 total portfolio adjustments, initiating 21 new buys, adding to 12 positions, trimming 33 holdings, and fully liquidating 23 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.